Computational Approaches for the Structure-Based Identification of Novel Inhibitors Targeting Nucleoid-Associated Proteins in Mycobacterium Tuberculosis
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
Implementation of computational tools in the identification of novel drug targets for Tuberculosis (TB) has been a promising area of research. TB has been a chronic infectious disease caused by Mycobacterium tuberculosis (Mtb) localized primarily on the lungs and it has been one of the most successful pathogen in the history of mankind. Extensively arising drug resistivity in TB has made it a global challenge and need for new drugs has become utmost important.The involvement of Nucleoid-Associated Proteins (NAPs) in maintaining the structure of the genomic material and regulating various cellular processes like transcription, DNA replication, repair and recombination makes significant, has opened a new arena to find the drugs targeting Mtb. The current study aims to identify potential inhibitors of NAPs through a computational approach. In the present work we worked on the eight NAPs of Mtb, namely, Lsr2, EspR, HupB, HNS, NapA, mIHF and NapM. The structural modelling and analysis of these NAPs were carried out. Moreover, molecular interaction were checked and binding energy was identified for 2500 FDA-approved drugs that were selected for antagonist analysis to choose novel inhibitors targeting NAPs of Mtb. Drugs including Amikacin, streptomycin, kanamycin, and isoniazid along with eight FDA-approved molecules that were found to be potential novel targets for these mycobacterial NAPs and have an impact on their functions. The potentiality of several anti-tubercular drugs as therapeutic agents identified through computational modelling and simulation unlocks a new gateway for accomplishing the goal to treat TB.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:66 |
|---|---|
| Enthalten in: |
Molecular biotechnology - 66(2024), 4 vom: 14. Apr., Seite 814-823 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sunita [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.04.2024 Date Revised 03.05.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12033-023-00710-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35418685X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35418685X | ||
| 003 | DE-627 | ||
| 005 | 20240503232058.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12033-023-00710-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1396.xml |
| 035 | |a (DE-627)NLM35418685X | ||
| 035 | |a (NLM)36913083 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sunita |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Computational Approaches for the Structure-Based Identification of Novel Inhibitors Targeting Nucleoid-Associated Proteins in Mycobacterium Tuberculosis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.04.2024 | ||
| 500 | |a Date Revised 03.05.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a Implementation of computational tools in the identification of novel drug targets for Tuberculosis (TB) has been a promising area of research. TB has been a chronic infectious disease caused by Mycobacterium tuberculosis (Mtb) localized primarily on the lungs and it has been one of the most successful pathogen in the history of mankind. Extensively arising drug resistivity in TB has made it a global challenge and need for new drugs has become utmost important.The involvement of Nucleoid-Associated Proteins (NAPs) in maintaining the structure of the genomic material and regulating various cellular processes like transcription, DNA replication, repair and recombination makes significant, has opened a new arena to find the drugs targeting Mtb. The current study aims to identify potential inhibitors of NAPs through a computational approach. In the present work we worked on the eight NAPs of Mtb, namely, Lsr2, EspR, HupB, HNS, NapA, mIHF and NapM. The structural modelling and analysis of these NAPs were carried out. Moreover, molecular interaction were checked and binding energy was identified for 2500 FDA-approved drugs that were selected for antagonist analysis to choose novel inhibitors targeting NAPs of Mtb. Drugs including Amikacin, streptomycin, kanamycin, and isoniazid along with eight FDA-approved molecules that were found to be potential novel targets for these mycobacterial NAPs and have an impact on their functions. The potentiality of several anti-tubercular drugs as therapeutic agents identified through computational modelling and simulation unlocks a new gateway for accomplishing the goal to treat TB | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Mycobacterium tuberculosis | |
| 650 | 4 | |a Inhibitors | |
| 650 | 4 | |a Molecular docking | |
| 650 | 4 | |a Molecular modelling | |
| 650 | 4 | |a Nucleoid-associated proteins | |
| 650 | 4 | |a Simulations | |
| 650 | 7 | |a Bacterial Proteins |2 NLM | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 650 | 7 | |a DNA-Binding Proteins |2 NLM | |
| 650 | 7 | |a Lsr2 protein, Mycobacterium tuberculosis |2 NLM | |
| 650 | 7 | |a HupB protein, Mycobacterium tuberculosis |2 NLM | |
| 650 | 7 | |a Histones |2 NLM | |
| 700 | 1 | |a Singhvi, Nirjara |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Vipin |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Yogendra |e verfasserin |4 aut | |
| 700 | 1 | |a Shukla, Pratyoosh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular biotechnology |d 1994 |g 66(2024), 4 vom: 14. Apr., Seite 814-823 |w (DE-627)NLM075082349 |x 1559-0305 |7 nnns |
| 773 | 1 | 8 | |g volume:66 |g year:2024 |g number:4 |g day:14 |g month:04 |g pages:814-823 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12033-023-00710-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 66 |j 2024 |e 4 |b 14 |c 04 |h 814-823 | ||